
## Coen Hemker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7979995/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exploring the limits of modelling thrombus formation. Physics of Life Reviews, 2018, 26-27, 100-105.	2.8	4
2	Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. Blood Advances, 2018, 2, 1315-1324.	5.2	27
3	Sex hormone-binding globulin and thrombin generation in women using hormonal contraception. Biomarkers, 2017, 22, 81-85.	1.9	12
4	Computational modelling of clot development in patientâ€specific cerebral aneurysm cases: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 395-396.	3.8	3
5	Computational modelling of clot development in patientâ€specific cerebral aneurysm cases: rebuttal. Journal of Thrombosis and Haemostasis, 2017, 15, 399-399.	3.8	1
6	Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1704-1707.	3.8	80
7	Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombosis and Haemostasis, 2016, 115, 869-870.	3.4	3
8	Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions. Thrombosis and Haemostasis, 2016, 116, 134-145.	3.4	8
9	Low paediatric thrombin generation is caused by an attenuation of prothrombin conversion. Thrombosis and Haemostasis, 2016, 115, 1090-1100.	3.4	21
10	A reduction of prothrombin conversion by cardiac surgery with cardiopulmonary bypass shifts the haemostatic balance towards bleeding. Thrombosis and Haemostasis, 2016, 116, 442-451.	3.4	13
11	A century of heparin: past, present and future. Journal of Thrombosis and Haemostasis, 2016, 14, 2329-2338.	3.8	56
12	Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation. Blood, 2015, 125, 1497-1501.	1.4	39
13	The application of thrombin generation in real life clinical situations. Thrombosis Research, 2015, 136, 3-4.	1.7	13
14	Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults. Thrombosis Research, 2015, 136, 1303-1309.	1.7	35
15	The balance of pro―and anticoagulant processes underlying thrombin generation. Journal of Thrombosis and Haemostasis, 2015, 13, 437-447.	3.8	55
16	Thrombin Generating Capacity and Phenotypic Association in ABO Blood Groups. PLoS ONE, 2015, 10, e0141491.	2.5	18
17	Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood, 2014, 123, 1098-1101.	1.4	242
18	The effect of fibrin(ogen) on thrombin generation and decay. Thrombosis and Haemostasis, 2014, 112, 486-494.	3.4	31

#	Article	IF	CITATIONS
19	A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X. Journal of Thrombosis and Haemostasis, 2013, 11, 503-511.	3.8	15
20	Data management in Thrombin Generation. Thrombosis Research, 2013, 131, 3-11.	1.7	99
21	Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factorÂIXa: a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 564.	3.8	4
22	Will One Size of Anticoagulant Dosage Fit All?. Drug Development Research, 2013, 74, 406-412.	2.9	3
23	Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica, 2013, 98, 549-554.	3.5	35
24	Is there value in kinetic modeling of thrombin generation? No (unless…). Journal of Thrombosis and Haemostasis, 2012, 10, 1470-1477.	3.8	41
25	Thrombin generation: What have we learned?. Blood Reviews, 2012, 26, 197-203.	5.7	144
26	No Effect of Ethanol Intake on Thrombin Generation Parameters. Thrombosis Research, 2012, 129, 530-531.	1.7	2
27	Whole-Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay. Clinical Chemistry, 2012, 58, 1252-1259.	3.2	100
28	Fluorogenic Peptideâ€Based Substrates for Monitoring Thrombin Activity. ChemMedChem, 2012, 7, 606-617.	3.2	20
29	Thrombin generation is extremely sensitive to preheating conditions. Journal of Thrombosis and Haemostasis, 2011, 9, 233-234.	3.8	25
30	Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. Journal of Thrombosis and Haemostasis, 2011, 9, 1549-1555.	3.8	23
31	Procoagulant effect of vitamin K antagonists?. Journal of Thrombosis and Haemostasis, 2011, 9, 2511-2512.	3.8	4
32	The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by α2â€macroglobulinâ€thrombin. Journal of Thrombosis and Haemostasis, 2010, 8, 1281-1289.	3.8	38
33	Monitoring new oral antithrombotics: what we should know before we can decide. Journal of Thrombosis and Haemostasis, 2010, 8, 2833-2835.	3.8	6
34	Monitoring platelet dependent thrombin generation in mice. Thrombosis Research, 2010, 126, 436-441.	1.7	23
35	Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay. Thrombosis Research, 2010, 126, 531-535.	1.7	27
36	The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution. Thrombosis and Haemostasis, 2009, 101, 165-170.	3.4	34

#	Article	IF	CITATIONS
37	The technique of measuring thrombin generation with fluorescent substrates: 4. The H-transform, a mathematical procedure to obtain thrombin concentrations without external calibration. Thrombosis and Haemostasis, 2009, 101, 171-177.	3.4	26
38	Recollections on thrombin generation. Journal of Thrombosis and Haemostasis, 2008, 6, 219-226.	3.8	36
39	Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. Thrombosis Research, 2008, 122, 237-245.	1.7	16
40	Recollections on thrombin generation. Journal of Thrombosis and Haemostasis, 2008, 6, 219-226.	3.8	15
41	Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica, 2007, 92, 714-715.	3.5	35
42	Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 753-758.	1.9	33
43	The contribution of ?2-macroglobulin thrombin to the endogenous thrombin potential. British Journal of Haematology, 2007, 139, 070916051811005-???.	2.5	7
44	Caution in the interpretation of continuous thrombin generation assays: a rebuttal. Journal of Thrombosis and Haemostasis, 2007, 5, 1085-1087.	3.8	11
45	Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. Journal of Thrombosis and Thrombolysis, 2007, 24, 175-182.	2.1	9
46	Low Molecular Weight Activated Protein C Inhibitors as a Potential Treatment for Hemophilic Disorders. Journal of Medicinal Chemistry, 2006, 49, 5047-5050.	6.4	21
47	Age-dependency of thrombin generation. Thrombosis and Haemostasis, 2006, 95, 756-757.	3.4	12
48	Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. Journal of Thrombosis and Haemostasis, 2006, 4, 83-89.	3.8	59
49	Mathematical and biological models of blood coagulation. A rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 710-711.	3.8	1
50	The limits of simulation of the clotting system. Journal of Thrombosis and Haemostasis, 2006, 4, 1331-1338.	3.8	51
51	New approaches for measuring coagulation. Haemophilia, 2006, 12, 76-81.	2.1	52
52	Laboratory monitoring of low-molecular-weight heparin therapy-part II. Journal of Thrombosis and Haemostasis, 2005, 3, 571-573.	3.8	12
53	During coagulation, thrombin generation shifts from chemical to diffusional control. Journal of Thrombosis and Haemostasis, 2005, 3, 2399-2400.	3.8	21
54	Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thrombosis and Haemostasis, 2005, 93, 475-480.	3.4	295

#	Article	IF	CITATIONS
55	Calibrated automated thrombinography (CAT). Thrombosis Research, 2005, 115, 255.	1.7	11
56	Factor Xl–Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1138-1142.	2.4	47
57	Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. Journal of Thrombosis and Haemostasis, 2004, 2, 170-176.	3.8	43
58	Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. Journal of Thrombosis and Haemostasis, 2004, 2, 1395-1401.	3.8	85
59	The love of the artist for his model of thrombin generation. Journal of Thrombosis and Haemostasis, 2004, 2, 400-401.	3.8	2
60	Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. Journal of Thrombosis and Haemostasis, 2004, 2, 476-484.	3.8	128
61	Phenotyping the haemostatic system by thrombography—potential for the estimation of thrombotic risk. Thrombosis Research, 2004, 114, 539-545.	1.7	65
62	Thrombin generation assays: accruing clinical relevance. Current Opinion in Hematology, 2004, 11, 170-175.	2.5	101
63	The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets. Journal of Thrombosis and Haemostasis, 2003, 1, 269-274.	3.8	19
64	von Willebrand factor stimulates thrombin-induced exposure of procoagulant phospholipids on the surface of fibrin-adherent platelets. Journal of Thrombosis and Haemostasis, 2003, 1, 559-565.	3.8	13
65	The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain. Journal of Thrombosis and Haemostasis, 2003, 1, 907-914.	3.8	49
66	Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH. Seminars in Thrombosis and Hemostasis, 2002, 28, 369-378.	2.7	14
67	The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 249-253.	0.3	566
68	Regulation of Platelet Factor Va-dependent Thrombin Generation by Activated Protein C at the Surface of Collagen-adherent Platelets. Journal of Biological Chemistry, 2001, 276, 7164-7168.	3.4	9
69	The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thrombosis and Haemostasis, 2000, 83, 589-91.	3.4	48
70	Phenotyping the clotting system. Thrombosis and Haemostasis, 2000, 84, 747-51.	3.4	32
71	Conjectures and Refutations on the Mode of Action of Heparins. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 170-178.	0.3	11
72	Inhibition of Tissue Factor-Factor VIIa-catalyzed Factor X Activation by Factor Xa-Tissue Factor Pathway Inhibitor. Journal of Biological Chemistry, 1999, 274, 28225-28232.	3.4	19

#	Article	IF	CITATIONS
73	Draculin, the anticoagulant factor in vampire bat saliva, is a tight-binding, noncompetitive inhibitor of activated factor X. BBA - Proteins and Proteomics, 1999, 1434, 135-142.	2.1	18
74	Heterogeneity in microparticle formation and exposure of anionic phospholipids at the plasma membrane of single adherent platelets. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1451, 163-172.	4.1	29
75	Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochimica Et Biophysica Acta - General Subjects, 1998, 1425, 291-299.	2.4	14
76	Prevention of the Influence of Fibrin and α2-Macroglobulin in the Continuous Measurement of the Thrombin Potential. Thrombosis Research, 1998, 89, 161-169.	1.7	29
77	Autocatalytic Peptide Bond Cleavages in Prothrombin and Meizothrombinâ€. Biochemistry, 1998, 37, 1185-1191.	2.5	32
78	Molecular Biology and Pathophysiology of APC Resistance: Current Insights and Clinical Implications. Seminars in Thrombosis and Hemostasis, 1998, 24, 329-335.	2.7	16
79	Prothrombin conversion under flow conditions by prothrombinase assembled on adherent platelets. Blood Coagulation and Fibrinolysis, 1997, 8, 168-174.	1.0	31
80	Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor*. Biochemical Journal, 1997, 323, 33-37.	3.7	22
81	Human Factor Va1and Factor Va2: Properties in the Procoagulant and Anticoagulant Pathwaysâ€. Biochemistry, 1997, 36, 3331-3335.	2.5	54
82	Purification and Characterization of Multisquamase, the Prothrombin Activator Present in Echis Multisquamatus Venom. Thrombosis Research, 1997, 88, 309-316.	1.7	21
83	The Ca2+-Mobilizing Potency of alpha-Thrombin and Thrombin-Receptor-Activating Peptide on Human Platelets. Concentration and Time Effects of Thrombin-Induced Ca2+ Signaling. FEBS Journal, 1997, 249, 547-555.	0.2	85
84	Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second―and thirdâ€generation oral contraceptives. British Journal of Haematology, 1997, 97, 233-238.	2.5	324
85	Can the Haemorrhagic Component of Heparin Be Identified? Or an Attempt at Clean Thinking on a Dirty Drug. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 117-126.	0.3	5
86	Synthesis of peptide <i>p</i> â€nitroanilides mimicking fibrinogen―and hirudinâ€binding to thrombin Design of slow reacting thrombin substrates. International Journal of Peptide and Protein Research, 1996, 48, 182-193.	0.1	7
87	Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis" Journal of Clinical Investigation, 1996, 98, 863-874.	8.2	362
88	A convenient synthesis of amino acid p-nitroanilides; synthons in the synthesis of protease substrates. Tetrahedron, 1995, 51, 11235-11250.	1.9	51
89	Prothrombin Contributes to the Assembly of the Factor Va-Factor Xa Complex at Phosphatidylserine-containing Phospholipid Membranes. Journal of Biological Chemistry, 1995, 270, 26883-26889.	3.4	29
90	Prothrombin Activation by Prothrombinase in a Tubular Flow Reactor. Journal of Biological Chemistry, 1995, 270, 1029-1034.	3.4	29

#	Article	lF	CITATIONS
91	Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor Va VaR506Q by Activated Protein C. Journal of Biological Chemistry, 1995, 270, 21158-21166.	3.4	215
92	Effects of Protein S and Factor Xa on Peptide Bond Cleavages during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C. Journal of Biological Chemistry, 1995, 270, 27852-27858.	3.4	207
93	Inhibition of Prothrombinase at Macroscopic Lipid Membranes: Competition between Antithrombin and Prothrombin. Biochemistry, 1995, 34, 13699-13704.	2.5	6
94	Design and synthesis of thrombin substrates with modified kinetic parameters. Thrombosis Research, 1995, 79, 491-499.	1.7	26
95	Production of thrombin as a probe for mixing of phospholipids in membranes on solid supports. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1237, 43-48.	2.6	5
96	Peptide p-nitroanilides: Chromogenic substrates for the determination of the thrombin generation curve. , 1995, , 901-902.		0
97	Inhibition of prothrombinase by antithrombin-heparin at a macroscopic surface. Thrombosis and Haemostasis, 1995, 73, 648-53.	3.4	2
98	Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thrombosis and Haemostasis, 1995, 74, 134-8.	3.4	52
99	Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 824-830.	3.9	39
100	Analysis of thrombin generation in plasma. Computers in Biology and Medicine, 1994, 24, 277-288.	7.0	33
101	Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochemical Journal, 1994, 297, 131-136.	3.7	42
102	A Chromogenic Test to Determine the Procoagulant Phospholipids in Platelet-rich Plasma and Whole Blood. Thrombosis and Haemostasis, 1994, 72, 582-587.	3.4	16
103	Measurement of thrombin generation in whole bloodthe effect of heparin and aspirin. Thrombosis and Haemostasis, 1994, 72, 78-83.	3.4	21
104	Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain. Journal of Biological Chemistry, 1994, 269, 20662-7.	3.4	37
105	Activation of human factor V by meizothrombin. Journal of Biological Chemistry, 1994, 269, 15969-72.	3.4	34
106	An investigation of the coagulological potential of the venoms of some Central Asian snakes. Chemistry of Natural Compounds, 1993, 29, 384-390.	0.8	0
107	Monitoring of unbound protein in vesicle suspensions with off-null ellipsometry. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1147, 125-131.	2.6	15
108	Development of a Rapid and Sensitive Chromogenic Heparin Assay for Clinical Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 26-37.	0.3	7

#	Article	IF	CITATIONS
109	Continuous Registration of Thrombin Generation in Plasma, Its Use for the Determination of the Thrombin Potential. Thrombosis and Haemostasis, 1993, 70, 617-624.	3.4	278
110	The Activity of Heparin in the Presence and Absence of Ca2+ lons; why the Anti-Xa Activity of LMW Heparins Is about two Times Overestimated. Thrombosis and Haemostasis, 1993, 70, 717-718.	3.4	15
111	Standard and Method Independent Units for Heparin Anticoagulant Activities. Thrombosis and Haemostasis, 1993, 70, 724-728.	3.4	15
112	The Influence of Oral Contraceptives on the Time-Integral of Thrombin Generation (Thrombin) Tj ETQq0 0 0 rgBT	/Oyerlock 3.4	10 Tf 50 622
113	Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thrombosis and Haemostasis, 1993, 70, 617-24.	3.4	63
114	Characterization of two forms of human factor Va with different cofactor activities. Journal of Biological Chemistry, 1993, 268, 21130-6.	3.4	51
115	Autoactivation of human blood coagulation factor XII on dextran derivatives of different molecular weight. Thrombosis Research, 1992, 67, 665-676.	1.7	11
116	Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma. British Journal of Haematology, 1992, 81, 255-262.	2.5	13
117	The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. FEBS Journal, 1992, 208, 171-178.	0.2	67
118	The Mode of Action of Heparins In Vitro and In Vivo. Advances in Experimental Medicine and Biology, 1992, 313, 221-230.	1.6	7
119	The Consumption of Antithrombin III During Coagulation, Its Consequences for the Calculation of Prothrombinase Activity and the Standardisation of Heparin Activity. Thrombosis and Haemostasis, 1992, 68, 136-142.	3.4	23
120	The mode of action of CY216 and CY222 in plasma. Thrombosis and Haemostasis, 1992, 67, 33-41.	3.4	4
121	A rational approach to heparins. , 1992, 34, 5-9.		0
122	Clustering of lipid-bound annexin V may explain its anticoagulant effect. Journal of Biological Chemistry, 1992, 267, 17907-12.	3.4	161
123	The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thrombosis and Haemostasis, 1992, 68, 136-42.	3.4	2
124	Procoagulant activities in venoms from central Asian snakes. Toxicon, 1991, 29, 491-502.	1.6	22
125	Surface exclusion and molecular mobility may explain Vroman effects in protein adsorption. Journal of Biomaterials Science, Polymer Edition, 1991, 2, 217-226.	3.5	14
126	Elements from in vitro studies that help understand the action of heparins. Thrombosis Research, 1991, 61, 1-10.	1.7	1

#	Article	IF	CITATIONS
127	Simulation Model for Thrombin Generation in Plasma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 197-207.	0.3	15
128	Feedback Mechanisms in Coagulation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 189-196.	0.3	6
129	Determination of the Levels of Unfractionated and Low-Molecular-Weight Heparins in Plasma: Their Effect on Thrombin-Mediated Feedback Reactions in vivo. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 258-272.	0.3	5
130	The use of phosphorus oxychloride in the synthesis of amino acid pâ€nitroanilides. Recueil Des Travaux Chimiques Des Pays-Bas, 1991, 110, 347-348.	0.0	16
131	A Method for Measuring Activated Factor VIII in Plasma. Thrombosis and Haemostasis, 1991, 66, 430-434.	3.4	0
132	The Mechanisms of Thrombin Formation. , 1991, , 3-16.		0
133	Mode of action of heparin and related drugs. Seminars in Thrombosis and Hemostasis, 1991, 17 Suppl 1, 29-34.	2.7	1
134	Membrane-mediated assembly of the prothrombinase complex. Journal of Biological Chemistry, 1991, 266, 18720-5.	3.4	34
135	Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma. Journal of Biological Chemistry, 1991, 266, 21864-73.	3.4	45
136	Mode of Action of Unfractionated and Low Molecular Weight Heparins on the Generation of Thrombin in Plasma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 81-92.	0.3	7
137	Development of a Sensitive and Rapid Chromogenic Factor IX Assay for Clinical Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 276-288.	0.3	8
138	Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, The, 1990, 335, 1544-1547.	13.7	1,294
139	Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers Journal of Biological Chemistry, 1990, 265, 4923-4928.	3.4	573
140	Mode of action of enoxaparin in plasma. Acta Chirurgica Scandinavica Supplementum, 1990, 556, 51-6.	0.1	4
141	Continuous flow and the prothrombinase-catalyzed activation of prothrombin. Thrombosis and Haemostasis, 1990, 64, 542-7.	3.4	8
142	Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. Journal of Biological Chemistry, 1990, 265, 4923-8.	3.4	433
143	Importance of Factor-IX-Dependent Prothrombinase Formation – The Josso Pathway – in Clotting Plasma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 301-308.	0.3	6
144	A Standard for Low Molecular Weight Heparin?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 1-4.	0.3	7

#	Article	IF	CITATIONS
145	Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochimica Et Biophysica Acta - General Subjects, 1989, 992, 409-411.	2.4	16
146	The ex Vivo Correlate of the Antithrombotic Action of Heparin. Annals of the New York Academy of Sciences, 1989, 556, 146-157.	3.8	14
147	Development of a Simple Chromogenic Factor VIII Assay for Clinical Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 196-204.	0.3	3
148	Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. Journal of Biological Chemistry, 1989, 264, 10002-10007.	3.4	27
149	The Effect of Trace Amounts of Tissue Factor on Thrombin Generation in Platelet Rich Plasma, its Inhibition by Heparin. Thrombosis and Haemostasis, 1989, 61, 025-029.	3.4	85
150	The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma. Thrombosis and Haemostasis, 1989, 61, 030-034.	3.4	44
151	The Action of a Synthetic Pentasaccharide on Thrombin Generation in Whole Plasma. Thrombosis and Haemostasis, 1989, 61, 397-401.	3.4	46
152	The Relative Importance of the Factors II, VII, IX and X for the Prothrombinase Activity in Plasma of Orally Anticoagulated Patients. Thrombosis and Haemostasis, 1989, 62, 788-791.	3.4	98
153	Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. Journal of Biological Chemistry, 1989, 264, 10002-7.	3.4	18
154	The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thrombosis and Haemostasis, 1989, 61, 25-9.	3.4	4
155	Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Inhibition of the phospholipid-dependent factor-Xa -catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phospholipids. FEBS Journal, 1988, 173, 171-178.	0.2	73
156	The prolongation of the thrombotest clotting time in newborns. Thrombosis Research, 1988, 52, 45-52.	1.7	1
157	Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation Journal of Biological Chemistry, 1988, 263, 15313-15318.	3.4	35
158	Isolation and partial characterization of a vitamin K-dependent carboxylase from bovine aortae. Biochemical Journal, 1987, 245, 251-255.	3.7	10
159	Spectrophotometric Method for the Assay of Human Blood Coagulation Factor VIII. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1987, 17, 14-24.	0.3	3
160	Adsorption Kinetics of Protein Mixtures A Tentative Explanation of the Vroman Effect. Annals of the New York Academy of Sciences, 1987, 516, 244-252.	3.8	39
161	THE ROLE OF HEPARIN CHARGE DENSITY IN THE ANTITHROMBIN III-DEPENDENT AND ANTITHROMBIN III-INDEPENDENT INACTIVATION OF THROMBIN. Thrombosis and Haemostasis, 1987, 58, 1558.	3.4	0
162	THE PROLONGATION OF THE THROMBOTEST CLOTTING TIME IN NEWBORNS. Thrombosis and Haemostasis, 1987, 58, 1470.	3.4	0

#	Article	IF	CITATIONS
163	THE MODE OF ACTION OF PENTOSAN POLYSULPHATE IN PLASMA. Thrombosis and Haemostasis, 1987, 58, 0450.	3.4	0
164	A NEW CASE OF A CONGENITAL COMBINED HYPO-DYSFIBRINOGENEMIA?. , 1987, 58, 0536.		0
165	GLA-CONTAINING PROTEINS FROM CALCIFIED HUMAN ATHEROSCLEROTIC PLAQUES. , 1987, 58, 0948.		0
166	INHIBITION OF FACTOR Xa AND THROMBIN BY ANTITHROMBIN III AND HEPARIN DURING HUMAN PROTHROMBIN ACTIVATION. Thrombosis and Haemostasis, 1987, 58, 0967.	3.4	0
167	DEVELOPMENT OF A SIMPLE FACTOR VIII-ASSAY FOR CLINICAL USE. Thrombosis and Haemostasis, 1987, 58, 1235.	3.4	0
168	The effect of factor Va on lipid dynamics in mixed phospholipid vesicles as detected by steady-state and time-resolved fluorescence depolarization of diphenylhexatriene. FEBS Journal, 1987, 164, 337-343.	0.2	4
169	The placental transport of [3H] vitamin K1in rats. British Journal of Haematology, 1987, 65, 335-338.	2.5	19
170	CLOTTING FACTOR DEPENDENCY OF PROTHROMBINASE ACTIVITY IN DICOUMAROL PLASMA. THE IMPORTANCE OF A FACTOR IX DEPENDENT PATHWAY IN EXTRINSIC COAGULATION. , 1987, 58, .		0
171	Thrombin generation and inactivation in the presence of antithrombin III and heparin. Biochemistry, 1986, 25, 5962-5969.	2.5	59
172	Inhibition of Thrombin-Catalyzed Reactions in Blood Coagulation and Platelet Activation by Heparin Fractions in the Absence of Antithrombin III. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 71-81.	0.3	4
173	Role of Accessory Components in the Activation of Vitamin K-Dependent Coagulation Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 216-226.	0.3	1
174	The activity state of factor VII in plasma: two pathways for the cold promoted activation of factor VII. British Journal of Haematology, 1986, 62, 367-377.	2.5	15
175	Kinetics of thrombin-induced release and activation of platelet factor V. FEBS Journal, 1986, 154, 213-218.	0.2	18
176	A Computer Assisted Method to Obtain the Prothrombin Activation Velocity in Whole Plasma Independent of Thrombin Decay Processes. Thrombosis and Haemostasis, 1986, 56, 009-017.	3.4	218
177	A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thrombosis and Haemostasis, 1986, 56, 9-17.	3.4	35
178	Vitamin K-dependent carboxylase: the carboxylation of exogenous substrates in different systems. BBA - Proteins and Proteomics, 1985, 831, 94-98.	2.1	9
179	Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. FEBS Journal, 1985, 151, 625-629.	0.2	164
180	Measurement of Macrophage Cellular Procoagulant Activity. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1985, 15, 108-113.	0.3	7

#	Article	lF	CITATIONS
181	The Mechanism of Action of Oral Anticoagulants and Its Consequences for the Practice of Oral Anticoagulation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1985, 15, 263-270.	0.3	9
182	Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients. Thrombosis Research, 1985, 37, 295-307.	1.7	10
183	Clotting factors secreted by monocytes and macrophages: Analytical considerations. Thrombosis Research, 1985, 37, 9-19.	1.7	28
184	Effect of heparin and low molecular weight heparins on thrombin-induced blood platelet activation in the absence of antithrombin III. Thrombosis Research, 1985, 38, 447-458.	1.7	8
185	Automated Spectrophotometric Heparin Assays. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 195-204.	0.3	1
186	The Inhibition of Platelet Prothrombinase Activity by Prostacyclin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 320-324.	0.3	3
187	Determination of Low Molecular Weight Heparin in Clinical Laboratory. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 205-210.	0.3	3
188	Heparin Neutralization during Collection and Processing of Blood Inhibited by Pyridoxal 5′-Phosphate. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 253-261.	0.3	2
189	Automated Determination of Heparin with Chromogenic Substrates. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 184-194.	0.3	1
190	Functional properties of factor Va subunits after proteolytic alterations by activated protein C. Biochimica Et Biophysica Acta - General Subjects, 1984, 799, 38-44.	2.4	15
191	Interaction of prothrombin with factor Va-phospholipid complexes. Biochemistry, 1984, 23, 2838-2842.	2.5	28
192	On the procoagulant activity of platelets stimulated by collagen and thrombin. Thrombosis Research, 1984, 33, 553-554.	1.7	7
193	The action of echis carinatus venom on the blood coagulation system. Demonstration of an activator of factor X. Thrombosis Research, 1984, 35, 1-9.	1.7	17
194	IN MEMORY OF FRANÇOIS JOSSO. Scandinavian Journal of Haematology, 1984, 33, 11-19.	0.0	2
195	The adsorption of prothrombin to phospholipid monolayers quantitated by ellipsometry Journal of Biological Chemistry, 1984, 259, 13993-13998.	3.4	53
196	The adsorption of prothrombin to phospholipid monolayers quantitated by ellipsometry. Journal of Biological Chemistry, 1984, 259, 13993-8.	3.4	35
197	Interaction of bovine blood clotting factor Va and its subunits with phospholipid vesicles. Biochemistry, 1983, 22, 2427-2432.	2.5	86
198	Editorial Note reduction of infarct size: discrepancies between experimental work and clinical application. International Journal of Cardiology, 1983, 2, 347-348.	1.7	1

#	Article	IF	CITATIONS
199	Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thrombosis Research, 1983, 32, 301-310.	1.7	32
200	Half-Life Time and Control Frequency of Vitamin K-Dependent Coagulation Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1983, 13, 201-208.	0.3	5
201	Stimulation of the vitamin K-dependent carboxylase from bovine liver. Biochemical Journal, 1983, 209, 719-724.	3.7	8
202	Measuring the conversion of a chromogenic substrate. , 1983, , 27-51.		1
203	Activation of human prothrombin by stoichiometric levels of staphylocoagulase Journal of Biological Chemistry, 1983, 258, 3637-3644.	3.4	77
204	The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry Journal of Biological Chemistry, 1983, 258, 2426-2431.	3.4	362
205	About the Cost of Opposing the Coumarin-Inhibitor Theory – Reply. Thrombosis and Haemostasis, 1983, 49, 247-247.	3.4	1
206	Determinations that can be carried out with chromogenic substrates. , 1983, , 95-123.		0
207	Substrates. , 1983, , 53-93.		Ο
208	Platelet membrane involvement in blood coagulation. Nouvelle Revue Française D'hématologie, 1983, 9, 303-17.	0.7	40
209	The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. Journal of Biological Chemistry, 1983, 258, 2426-31.	3.4	256
210	Activation of human prothrombin by stoichiometric levels of staphylocoagulase. Journal of Biological Chemistry, 1983, 258, 3637-44.	3.4	64
211	A comparison between vitamin K-dependent carboxylase from normal and warfarin-treated cows. Biochimica Et Biophysica Acta - General Subjects, 1982, 714, 361-365.	2.4	27
212	Factor Va-factor Xa interaction. Effects of phospholipid vesicles of varying composition. Biochemistry, 1982, 21, 5494-5502.	2.5	112
213	Interindividual variation in relationships between plasma heparin concentration and the results of five heparin assays. Clinica Chimica Acta, 1982, 122, 261-270.	1.1	25
214	The inhibition of vitamin K-dependent carboxylase by cyanide. FEBS Letters, 1982, 137, 253-256.	2.8	20
215	Heterogeneous biocatalysis in the generation of thrombin. Trends in Biochemical Sciences, 1982, 7, 378-381.	7.5	5
216	Use of Chromogenic Peptide Substrates in the Determination of Clotting Factors II, VII, IX and X in Normal Plasma and in Plasma of Patients Treated with Oral Anticoagulants. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1982, 12, 241-255.	0.3	5

#	Article	IF	CITATIONS
217	On the Clot-Promoting Activity of Human Platelets in a One-Stage Prothrombinase Assay. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1982, 12, 268-274.	0.3	7
218	Generation of Prothrombin-Converting Activity and the Exposure of Phosphatidylserine at the Outer Surface of Platelets. FEBS Journal, 1982, 122, 429-436.	0.2	426
219	Studies on the mechanism of the vitamin K-dependent carboxylation reaction. Carboxylation without the concurrent formation of vitamin K 2,3-epoxide Journal of Biological Chemistry, 1982, 257, 5326-5329.	3.4	23
220	Activation of Factor IX by Factor XIa - A Spectrophotometric Assay for Factor IX in Human Plasma. Thrombosis and Haemostasis, 1982, 48, 127-132.	3.4	6
221	Studies on the mechanism of the vitamin K-dependent carboxylation reaction. Carboxylation without the concurrent formation of vitamin K 2,3-epoxide. Journal of Biological Chemistry, 1982, 257, 5326-9.	3.4	18
222	Partial purification of bovine liver vitamin K-dependent carboxylase by immunospecific adsorption onto antifactor X. FEBS Letters, 1981, 123, 215-218.	2.8	52
223	In vitro prothrombin synthesis from a purified precursor protein III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin. Biochimica Et Biophysica Acta - General Subjects, 1981, 676, 101-107.	2.4	31
224	Thrombosis service in The Netherlands. International Journal of Cardiology, 1981, 1, 215-216.	1.7	0
225	A New Method To Determine The Binding Of Factor X To Phospholipid Bilayers. Thrombosis and Haemostasis, 1981, 46, 0263.	3.4	0
226	Inhibition of Activated Factors II, VII, IX, and X by Synthetic Organic Compounds Directed against the Active-Site Seryl Residue. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1981, 10, 315-347.	0.3	0
227	Activation of Bovine Factor IX By Bovine Factor XIa . Active Site Titration Of Factor IXa and Development of A spectro-Photometric assay for Factor IX. Thrombosis and Haemostasis, 1981, 46, .	3.4	1
228	The role of phospholipid and factor VIIIa in the activation of bovine factor X. Journal of Biological Chemistry, 1981, 256, 3433-42.	3.4	393
229	Identification of phospholipid as an essential part of bovine vitamin K-dependent carboxylase. Journal of Biological Chemistry, 1981, 256, 10843-6.	3.4	22
230	Contribution of the Platelet Factor V Content to Platelet Factor 3 Activity. British Journal of Haematology, 1980, 45, 121-131.	2.5	7
231	Temperature dependent transitions in several phospholipids measured by ellipsometry. Surface Science, 1980, 96, 555-563.	1.9	7
232	ORAL TREATMENT OF HÆMOPHILIA A BY GASTROINTESTINAL ABSORPTION OF FACTOR VIII ENTRAPPED IN LIPOSOMES. Lancet, The, 1980, 315, 70-71.	13.7	43
233	The role of phospholipids and factor Va in the prothrombinase complex. Journal of Biological Chemistry, 1980, 255, 274-83.	3.4	454
234	Control of Anticoagulant Therapy with a Chromogenic Substrate. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1979, 8, 1-7.	0.3	2

#	Article	IF	CITATIONS
235	Clot-Promoting Effect of Platelet-Vessel Wall Interaction: Influence of Dietary Fats and Relation to Arterial Thrombus Formation in Rats. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1979, 8, 211-226.	0.3	9
236	Lipid Phase Transitions and Procoagulant Activity. FEBS Journal, 1979, 95, 449-457.	0.2	38
237	A coagulation reagent completely devoid of factor X; Relation between clotting time and concentration of factor X. Thrombosis Research, 1979, 14, 679-685.	1.7	1
238	An inhibitor of clot formation in cord plasma. Thrombosis Research, 1979, 15, 389-403.	1.7	1
239	The Role of Surfaces in the Mechanism of Blood Coagulation. , 1979, , 134-158.		1
240	Purification and properties of the phenprocoumon-induced decarboxyfactor X from bovine plasma. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 302-317.	1.7	15
241	The role of γ-carboxyglutamyl residues in the positive cooperative binding of Ca2+ to blood coagulation factor X. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 318-326.	1.7	19
242	Activation of decarboxyfactor X by a protein from Russell's Viper venom. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 327-341.	1.7	22
243	The effect of γ-carboxyglutamate residues on the enzymatic properties of the activated blood clotting factor X. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 342-354.	1.7	12
244	Ellipsometry as a tool to study protein films at liquid-solid interfaces. Analytical Biochemistry, 1978, 84, 56-67.	2.4	102
245	The determination of prothrombin using synthetic chromogenic substrates; choice of a suitable activator. Thrombosis Research, 1978, 13, 219-232.	1.7	52
246	A quick method for the determination of decarboxyfactor X. Thrombosis Research, 1978, 12, 1071-1078.	1.7	0
247	Improvements of the method for the preparation of an artificial prothrombin reagent. Thrombosis Research, 1978, 12, 713-716.	1.7	3
248	The role of blood clotting factor V in the conversion of prothrombin and A decarboxy prothrombin into thrombin. Biochimica Et Biophysica Acta - General Subjects, 1978, 538, 521-533.	2.4	18
249	Computer evaluation of reference curves for the estimation of extrinsic coagulation factors. Computers in Biology and Medicine, 1978, 8, 65-70.	7.0	4
250	In vitro prothombin sysnthesis from a purified precursor protein. II. Partial purification of bovine carboxylase. Biochimica Et Biophysica Acta - Biomembranes, 1978, 523, 494-505.	2.6	14
251	VITAMIN-K DEFICIENCY IN THE NEWBORN. Lancet, The, 1977, 310, 708-709.	13.7	9
252	HEPARIN-LIKE INHIBITOR, NOT VITAMIN-K DEFICIENCY, IN THE NEWBORN. Lancet, The, 1977, 309, 852-853.	13.7	41

#	Article	IF	CITATIONS
253	Reconstitution and lipid requirements of porcine tissue thromboplastin. Lipids and Lipid Metabolism, 1977, 488, 161-171.	2.6	6
254	A new method for the preparation of artificial factor II reagents from normal human and bovine plasma. Thrombosis Research, 1977, 10, 495-507.	1.7	14
255	Partial Purification of the Protein Moiety of Porcine Tissue Thromboplastin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1977, 6, 269-282.	0.3	2
256	Paratopic interaction, a mechanism in the generation of structure bound enzymatic activity. Experientia, 1977, 33, 851-853.	1.2	1
257	Heparin-like inhibitor of blood coagulation in normal newborn. Nature, 1977, 267, 616-617.	27.8	16
258	ELLIPSOMETRIC STUDY OF PROTEIN FILM ON CHROMIUM. Annals of the New York Academy of Sciences, 1977, 283, 77-85.	3.8	57
259	BLOOD COAGULATION FACTORS AT PHOSPHOLIPID SURFACES. Annals of the New York Academy of Sciences, 1977, 283, 104-110.	3.8	26
260	The Synthesis of Prothrombin from Its Precursor Protein. Current Studies in Hematology and Blood Transfusion, 1977, 44, 54-60.	0.2	1
261	Kinetic Aspects of the Interaction of Blood Clotting Enzymes. Thrombosis and Haemostasis, 1977, 37, 081-085.	3.4	7
262	In vitro prothrombin synthesis from a purified precursor protein I. Development of a bovine liver cell-free system. Biochimica Et Biophysica Acta - General Subjects, 1976, 444, 926-930.	2.4	17
263	Kinetics of the formation of the factor X activating enzyme of the blood coagulation system. Thrombosis Research, 1976, 8, 303-317.	1.7	24
264	The influence of glycerol on the Ca flux in the isolated perfused rat heart. Basic Research in Cardiology, 1976, 71, 252-262.	5.9	0
265	Purification and properties of staphylocoagulase. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 379, 164-171.	1.7	16
266	The influence of cadmium ions on the adsorption of prothrombin onto Al(OH)3 as a means to purify prothrombin. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 379, 172-179.	1.7	8
267	Activation of a pro-enzyme by a stoichiometric reaction with another protein. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 379, 180-188.	1.7	84
268	Quantitation of infarct size in man by means of plasma enzyme levels Heart, 1975, 37, 795-803.	2.9	90
269	Discrepancies between the One- and Two-Stage Prothrombin Estimations in Purified Prothrombin Preparations. , 1975, , 89-92.		0
270	Different Properties of Factor VIII in Von Willebrand's Disease with Respect to Recovery in Cryoprecipitate. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1974, 3, 142-148.	0.3	0

#	Article	IF	CITATIONS
271	Demonstration of three anomalous plasma proteins induced by a vitamin K antagonist. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1973, 317, 559-562.	1.7	46
272	Enzymes and Paraenzymes in the Sequential Reactions in Blood Coagulation. Biochemical Society Transactions, 1973, 1, 1189-1191.	3.4	0
273	Inhibition of blood coagulation factors by serine esterase inhibitors. FEBS Letters, 1972, 24, 265-268.	2.8	2
274	Estimation of the rate constants in the michaelis-menten equations without restrictions as to time scale. FEBS Letters, 1972, 24, 293-295.	2.8	1
275	Differential Interaction of Clotting Factors II, VII, IX and X with Sephadex and Dextran Blue. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1972, 1, 237-252.	0.3	0
276	Artificial Reagents for Factor VII and Factor X, a Computer Programme for Obtaining Reference Tables for One-Stage Determinations in the Extrinsic System. Thrombosis and Haemostasis, 1972, 27, 205-211.	3.4	14
277	Studies on Blood Coagulation Factor V. Thrombosis and Haemostasis, 1972, 27, 025-032.	3.4	5
278	Studies on Blood Coagulation Factor V. Thrombosis and Haemostasis, 1972, 27, 033-042.	3.4	3
279	Artificial reagents for factor VII and factor X, a computer programme for obtaining reference tables for one-stage determinations in the extrinsic system. Thrombosis Et Diathesis Haemorrhagica, 1972, 27, 205-11.	0.2	8
280	The Evaluation of the Two-Stage Prothrombin Assay. Thrombosis and Haemostasis, 1971, 25, 545-554.	3.4	7
281	CONTROL OF LONG-TERM ANTICOAGULANT TREATMENT. Lancet, The, 1970, 295, 894.	13.7	1
282	Separation of blood coagulation factors II , VII, IX and X by cel filtration in the presence of Dextran blue. Biochimica Et Biophysica Acta - General Subjects, 1970, 222, 692-695.	2.4	40
283	Two Types of Prothrombin in Vitamin K Deficiency. Thrombosis and Haemostasis, 1970, 23, 633-637.	3.4	25
284	The Adsorption of Coagulation Factors onto Phospholipids. Thrombosis and Haemostasis, 1970, 24, 214-223.	3.4	15
285	Anticoagulants in Acute Myocardial Infarction. BMJ: British Medical Journal, 1969, 2, 445-445.	2.3	1
286	The Thrombotest Dilution Curve and Its Diagnostic Significance. , 1969, , 365-368.		4
287	Studies on Blood Coagulation Factor V. Thrombosis and Haemostasis, 1969, 22, 417-430.	3.4	6
288	Enzyme Kinetic Evaluation of Coagulation Systems. , 1969, , 104-110.		0

#	Article	IF	CITATIONS
289	Reaction Sequence of Blood Coagulation. Nature, 1967, 215, 1201-1202.	27.8	98
290	Formation of Prothrombin Converting Activity. Nature, 1967, 215, 248-251.	27.8	78
291	A Doubleâ€blind Trial of Longâ€term Anticoagulant Treatment after Myocardial Infarction. Acta Medica Scandinavica, 1967, 182, 549-566.	0.0	118
292	Kinetic Aspects of the Interaction of Blood Clotting Enzymes. Thrombosis and Haemostasis, 1965, 13, 155-175.	3.4	7
293	Detection of heterozygotes for factor 8, 9, and 12 deficiency. Thrombosis Et Diathesis Haemorrhagica Supplementum, 1965, 17, 181-9.	0.0	1
294	Nature of Prothrombin Biosynthesis : Preprothrombinæmia in Vitamin K-deficiency. Nature, 1963, 200, 589-590.	27.8	121